ArticleOncotarget2016

Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions.

Feifei Teng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.